Designing a First-in-Human Study of a Systemically Administered AAV Micro-Dystrophin Gene Therapy in Ambulatory Boys with Duchenne Muscular Dystrophy: Scientific and Regulatory Rationale and Phase 1 Protocol Synopsis
A single systemic infusion of an AAV vector at doses near 10 to the power of 14 vector genomes per kilogram cannot be undone, and the vector load, not the body surface area, determines most of its risks. This article develops the scientific and regulatory rationale and a complete protocol synopsis for a hypothetical first-in-human study of a systemically administered AAV micro-dystrophin gene therapy in ambulatory boys aged 4 to under 8 years with Duchenne muscular dystrophy. It proposes an open-label, non-randomized, single-ascending-dose study of 12 participants in two dose cohorts of four (6.6 x 10 to the power of 13 and 1.33 x 10 to the power of 14 vector genomes per kilogram) with an optional third cohort, sentinel dosing with a 14-day observation, mandatory pre-dose antibody screening, prophylactic corticosteroids, intensive weekly liver monitoring for 12 weeks, explicit hepatic and immune stopping rules, and long-term follow-up of at least 5 years. Micro-dystrophin expression is a co-primary biological endpoint and motor function is exploratory. All nonclinical values and doses are illustrative assumptions, and the article treats class-level risks as design inputs and not as findings about any product.Keywords: first-in-human; AAV gene therapy; micro-dystrophin; Duchenne muscular dystrophy; pediatric Phase 1; hepatic monitoring; long-term follow-up
Authors
- Kishan Rajput
- Peivand Pirouzi
- Pruthvirajsinh Sindha
- Sukhpreet Singh Maan
- Vraj Modi
Institutions
- Northeastern University (US)
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-21
- DOI
- https://doi.org/10.5281/zenodo.24426593
- Primary Topic
- Virus-based gene therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00